论文部分内容阅读
目的探讨格列喹酮治疗老年糖尿病肾病的临床疗效。方法选取桂林市灵川县人民医院2015年1月—2016年10月收治的老年糖尿病肾病患者80例,按照随机数字表法将患者分成对照组与观察组,各40例。对照组患者给予普通胰岛素治疗,观察组患者给予格列醛酮治疗,两组患者均连续治疗3个月。比较两组患者治疗前后糖化血红蛋白(HbA1c)、血肌酐(Scr)、尿微量清蛋白(U-ALB)、α_1-微球蛋白(α1-MG)、血β_2-微球蛋白(β_2-MG)、血清胱抑素C(CysC)水平及临床疗效。结果治疗前两组患者HbA1c、Scr、U-ALB、α_1-MG、β_2-MG、CysC水平比较,差异无统计学意义(P>0.05);治疗后两组患者HbA1c、Scr水平比较,差异无统计学意义(P>0.05);治疗后U-ALB、α_1-MG、β_2-MG、CysC水平低于对照组(P<0.05)。观察组患者治疗总效率为92.5%,高于对照组的72.5%(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论格列喹酮治疗老年糖尿病肾病的临床疗效确切,可增强对患者肾脏的保护作用,安全性高。
Objective To investigate the clinical efficacy of gliquidone in the treatment of senile diabetic nephropathy. Methods Eighty elderly diabetic nephropathy patients were treated in Lingchuan County People’s Hospital of Guilin from January 2015 to October 2016. The patients were divided into control group and observation group according to random number table method, 40 cases in each group. Patients in the control group were treated with normal insulin, and patients in the observation group were given glenolone. Patients in both groups were treated continuously for 3 months. The levels of HbA1c, Scr, U-ALB, α1-microglobulin (α1-MG) and β_2-microglobulin (β_2-MG) , Serum cystatin C (CysC) levels and clinical efficacy. Results There was no significant difference in HbA1c, Scr, U-ALB, α_1-MG, β_2-MG and CysC between the two groups before treatment (P> 0.05). There was no significant difference in HbA1c and Scr between the two groups Statistically significant (P> 0.05). After treatment, the levels of U-ALB, α 1-MG, β 2-MG and CysC were lower than those of the control group (P <0.05). The total effective rate of observation group was 92.5%, which was higher than that of control group (72.5%, P <0.05). The incidence of adverse reactions in observation group was lower than that in control group (P <0.05). Conclusion The clinical efficacy of gliquidone in the treatment of diabetic nephropathy in elderly patients is definite, which can enhance the protective effect on the kidneys of the patients with high safety.